Tue, 14 July 2015
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.
Direct download: GRACEcast-342_ASCO_2015_Improved_Survival_Malignant_Pleural_Mesothelioma.mp4
Category:Lung-Cancer-Video -- posted at: 12:24pm PDT